证券代码：301509 证券简称：金凯生科 公告编号：2025-019 金凯（辽宁）生命科技股份有限公司 关于持股5%以上股东持股比例降至5%以下 股东启鹭（厦门）股权投资合伙企业（有限合伙）保证向本公司提供的信息 内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 本次权益变动属于持股5%以上股东启鹭（厦门）股权投资合伙企业（有限合伙） （以下简称"启鹭投资"）实施前期已披露的股份减持计划。 本次权益变动后，启鹭投资持有公司股份602.2280万股，占公司总股本的 4.99996%，不再是公司持股5%以上的股东。 本次权益变动不会导致公司的控股股东、实际控制人发生变化。 金凯（辽宁）生命科技股份有限公司（以下简称"公司"）于近日收到启鹭投资送 达的《告知函》及《简式权益变动报告书》，获悉启鹭投资通过集中竞价方式和大宗 交易方式累计减持公司股份447.7720万股，持股数量降至602.2280万股，占公司总股 本比例4.99996%，不再是公司持股5%以上的股东。现将具体情况公告如下： 一、本次权益变动的基本情况 暨权益变 ...

金凯（辽宁）生命科技股份有限公司 简式权益变动报告书 上市公司名称：金凯（辽宁）生命科技股份有限公司 信息披露义务人：启鹭（厦门）股权投资合伙企业（有限合伙） 注册地址：厦门市湖里区金山街道云顶北路16号308单元A389 通讯地址：厦门市湖里区金山街道云顶北路16号308单元A389 股份变动性质：股份减少，持股比例下降 签署日期：2025年7月28日 股票上市地点：深圳证券交易所 股票简称：金凯生科 股票代码：301509 信息披露义务人声明 1、本报告书系信息披露义务人依据《中华人民共和国证券法》《上市公司收 购管理办法》《公开发行证券的公司信息披露内容与格式准则第15号——权益变动 报告书》及其他相关法律、法规及规范性文件的有关规定编写。 2、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人合伙协议或内部规章中的任何条款，或与之相冲突。 3、依据《中华人民共和国证券法》《上市公司收购管理办法》《公开发行证 券的公司信息披露内容与格式准则第15号——权益变动报告书》的规定，本报 告书已全面披露信息披露义务人在金凯（辽宁）生命科技股份有限公司拥有权 益的股份变动情况。 截至 ...

Group 1 - The company, Jinkai Biotechnology (301509), positions itself as a global small molecule CDMO service provider in the life sciences sector [1] - The main services offered by the company include process development, process optimization, process scale-up, and large-scale production for clients in the innovative drug development process [1]

Group 1 - The core viewpoint of the news is that the implementation of the national childcare subsidy policy is expected to significantly benefit the infant and child industry, leading to a surge in stock prices of related companies [1][2] - The childcare subsidy will be issued annually at a base standard of 3600 yuan per child, covering all families with children under three years old, regardless of the number of children [1][2] - The policy aims to alleviate the financial burden of raising children, thereby increasing the willingness to have more children and fostering a family-friendly social environment [2] Group 2 - Companies such as Beimei and Aiyingshi have seen their stock prices rise sharply, with some stocks hitting the daily limit, indicating strong market confidence in the benefits of the subsidy policy [1][2] - The implementation of the subsidy is expected to increase disposable income for families with infants, positively impacting the sales of baby products, milk powder, toys, and clothing [2] - The policy is supported by a special transfer payment fund from the central government, ensuring timely and sufficient distribution of funds to families [2]

Group 1 - The core viewpoint of the articles highlights the financial performance of Jinkai Biotechnology, showcasing significant growth in Q1 2025 compared to the previous year, despite a decline in 2024 [1] - In Q1 2025, the company achieved operating revenue of 176 million yuan, a year-on-year increase of 41.83%, and a net profit attributable to shareholders of 47.42 million yuan, up 183.24% [1] - For the year 2024, the company reported operating revenue of 497 million yuan, a decrease of 35.19%, and a net profit attributable to shareholders of 38.61 million yuan, down 77.76% [1] Group 2 - Jinkai Biotechnology raised a total of 1.22 billion yuan from its initial public offering, with a net amount of approximately 1.11 billion yuan after deducting issuance costs, exceeding the original plan by 310 million yuan [2] - The company plans to use the raised funds for pharmaceutical intermediates, high-end pharmaceutical products, and to supplement working capital [2] - The annual equity distribution plan for 2023 includes a cash dividend of 8 yuan for every 10 shares and a capital reserve conversion of 4 additional shares for every 10 shares held [2] Group 3 - The actual controllers of Jinkai Biotechnology are Fumin Wang and Lianping Wu, both of whom hold American nationality [3]

Group 1 - The CRO concept sector has seen a significant rise, with companies like Lianhua Technology (002250) hitting the daily limit up, indicating strong investor interest [1] - Ruizhi Pharmaceutical (300149) has increased by over 10%, reflecting positive market sentiment towards the CRO sector [1] - Other companies such as Meinuohua (603538), Jinkai Biotechnology (301509), Shengnuo Biotech, Wanbang Pharmaceutical (301520), and Haoyuan Pharmaceutical have also experienced gains, showcasing a broader trend in the industry [1]

Group 1 - Weijie Chuangxin plans to reduce its shareholding by up to 3%, amounting to no more than 12.91 million shares, due to personal funding needs [1] - Lier Chemical's major shareholder intends to reduce its stake by up to 3%, equivalent to no more than 24.01 million shares, for investment returns [1] - Helin Micro-Nano's controlling shareholder plans to reduce its shareholding by up to 1.5%, which is no more than 1.75 million shares, due to personal funding needs [2] Group 2 - Yifan Pharmaceutical received drug registration certificates for two products, indicating a focus on oncology and leukemia treatments [3] - *ST Jinbi is planning a change in control, leading to a temporary suspension of its stock trading [4] - Kexing Pharmaceutical's shareholder plans to reduce its stake by up to 3%, amounting to no more than 5.90 million shares, to optimize the equity structure [7] Group 3 - Li New Energy plans to invest approximately 1.25 billion yuan in three independent energy storage projects [7] - Kingsoft Office intends to acquire the remaining 31.98% stake in its subsidiary for 254 million yuan, aiming for full ownership [8] - Northeast Pharmaceutical received a CEP certificate from the European Medicines Agency for an antibiotic raw material, enhancing its product credibility [9] Group 4 - Tai'er Co. announced the lifting of a detention order on its controlling shareholder, changing it to a notice of supervision [10] - Runjian Co. won a bid for a solar power project worth approximately 83.92 million yuan, highlighting its role in the energy sector [11] - Jiuan Medical plans to register and issue medium-term notes and short-term financing bonds, with a total scale of up to 35 billion yuan and 5 billion yuan respectively [12] Group 5 - Wanma Co.'s chairman resigned due to work adjustments, but will remain as a board member [13] - Changhua Chemical plans to transfer 1% of its shares through an inquiry transfer method due to personal funding needs [14] - Jinkai Biotechnology's two shareholders plan to reduce their combined stake by up to 4%, totaling 481.6 thousand shares [15] Group 6 - Aeston plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy [16] - Maiwei Biotechnology's chairman proposed a share buyback plan with a total amount between 25 million and 50 million yuan [17] - Montai High-tech's specific shareholders and executives plan to reduce their stake by up to 3.03%, citing personal funding needs [18] Group 7 - *ST Dongjing's stock will resume trading after a change in control, with a new actual controller [20] - Tongdahai's major shareholders plan to reduce their combined stake by up to 3.57%, totaling 345.24 thousand shares [23]

金凯生科股东青松投资持有公司股份4,801,374股(占公司总股本比例3.99%)。青松投资计划通过集中竞 价方式减持公司股份不超过1,204,000股，减持比例不超过公司总股本的1%。集中竞价的减持期间为自 本减持计划公告之日起十五个交易日后的三个月内。 中国经济网北京6月5日讯金凯生科（301509）(301509.SZ)昨晚披露的关于公司股东减持股份的预披露 公告显示，公司于近日分别收到股东启鹭(厦门)股权投资合伙企业(有限合伙)(以下简称"启鹭投资")、青 岛青松创业投资集团有限公司-青岛松凯创业投资企业(有限合伙)(以下简称"青松投资")提交的《关于减 持金凯(辽宁)生命科技股份有限公司股份计划的告知函》。 金凯生科股东启鹭投资持有公司股份7,140,500股(占公司总股本比例5.93%)。启鹭投资计划通过集中竞 价和大宗交易方式减持公司股份不超过3,612,000股(占公司总股本比例3%)。其中，通过集中竞价方式减 持股份不超过1,204,000股，减持比例不超过公司总股本的1%；通过大宗交易方式减持股份不超过 2,408,000股，减持比例不超过公司总股本的2%。集中竞价或大宗交易的减持期间为自 ...

Core Viewpoint - The A-share medical service sector experienced a short-term decline, with significant drops in several companies' stock prices, indicating potential market volatility in this industry [1] Company Summary - Jinkai Biotechnology saw a decline of over 8% in its stock price [1] - Other companies that followed the downward trend include Sunshine Nuohuo, Tigermed, Hongbo Pharmaceutical, Berry Genomics, and Chengdu Xian Dao [1]

Group 1 - The healthcare sector has experienced a short-term decline, with Jinkai Biotechnology (301509) dropping over 8% [1] - Other companies such as Hongbo Pharmaceutical (301230), Baicheng Pharmaceutical (301096), Chengdu XianDao, and Wanbang Pharmaceutical (301520) also saw declines [1] - There is a notable influx of dark pool capital into these stocks, indicating potential interest from institutional investors [1]